A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis

British Journal of Clinical Pharmacology

Volumn 58, Issue 6, 2004, Pages 618-631

  Pillai, Goonaseelan ^a,b,f   Gieschke, Ronald ^a,c   Goggin, Timothy ^a,b   Jacqmin, Philippe ^e,g   Schimmer, Ralph C ^d   Steimer, Jean Louis ^a,c,f  

^a Modelling and Simulation Team   (Switzerland)

^b F Hoffmann La Roche   (Switzerland)

^c Biostatistics   (Switzerland)

^d Medical Science   (Switzerland)

^e PHARSIGHT CORPORATION   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Exprimo Consulting LLP   (United Kingdom)

Author keywords

Ibandronate; Modelling and simulation; NONMEM; Osteoporosis; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID; VITAMIN D;

CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONFERENCE PAPER; CURVE FITTING; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG RESPONSE; FEMALE; HUMAN; NONLINEAR MIXED EFFECT MODEL; NONLINEAR SYSTEM; OSTEOPOROSIS; PERFORMANCE; PHARMACODYNAMICS; PHARMACOKINETIC PHARMACODYNAMIC MODEL; PHARMACOKINETICS; PLASMA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SIMULATION; URINARY EXCRETION; URINE; VALIDATION PROCESS;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; BONE RESORPTION; CLINICAL TRIALS; COLLAGEN; COLLAGEN TYPE I; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFUSIONS, INTRAVENOUS; MODELS, BIOLOGICAL; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; TREATMENT OUTCOME;

EID: 10844265575     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02224.x     Document Type: Conference Paper

References (40)

1. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
2. Riggs BL, Melton LJ 3rd. The prevention and treatment of osteoporosis. N Engl J Med 1992; 327: 620-7.
3. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999; 9: S66-S80.
4. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018-26.
5. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions and discontinuation. J Managed Care Pharm 1998; 4: 488-92.
6. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002; 24: 1871-86.
7. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996; 19: 527-33.
8. Delmas PD, Recker R, Stakkestad JA et al. Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study. Osteoporos Int 2002; 13: S15 (Abstract O37).
9. Cooper C, Emkey R, McDonald R et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 4609-15.
10. Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001; 16: 1871-8.
11. Thiebaud D, Burckhardt P, Kriegbaum H et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298-307.
12. Recker RR, Stakkestad JA, Felsenberg D et al. A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial. Osteoporos Int 2000; 11: S209 (Abstract 565).
13. Adami S, Delmas PD, Felsenberg D et al. Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Osteoporos Int 2002; 13: S14 (Abstract O36).
14. Johnson S. The role of simulation in the management of research: what can the pharmaceutical industry learn from the aerospace industry? Drug Inf J 1998; 32: 961-9.
15. Kaufmann WJ, Smarr LL. Supercomputing and the Transformation of Science. New York: Scientific American Library, 1993.
16. Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, Van Brummelen P. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 1997; 33: 142-52.
17. Cieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet 2000; 25: 49-58.
18. Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40: 209-34.
19. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modelling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95.
20. Goggin T, Gieschke R, Pillai G, Fotteler B, Jordan P, Steimer JL. Modeling and simulation of clinical trials: an industry perspective. In Simulation for Designing Clinical Trials: a Pharmacokinetic-Pharmacodynamic Modelling Perspective, eds Kimko H, Duffull SB. New York: Marcel Dekker, 2002.
21. Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997; 35: 469-74.
22. Hale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672-83.
23. Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68: 677-87.
24. Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 30: 320-4.
25. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM User Guide, Part V. University of California, San Francisco: NONMEM Project Group, 1984.
26. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-78.
27. Gabrielsson J, Jusko WJ, Alari L. Modelling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos 2000; 2: 41-52.
28. Jacqmin P, Gieschke R, Jordan P, Steimer JL, Goggin T, Pillai G. Modelling Drug Induced Changes in Biomarkers Without Using Drug Concentrations: Introducing the K-PD Model. 10th Population Approach Group Conference, Basel, Switzerland, http://www.page-meeting.org 2001.
29. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modelling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71.
30. American Association of Clinical Endocrinologists (AACE) medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001; 7: 294-312.
31. Pillai G, Gieschke R, Goggin T, Steimer JL. Population Pharmacokinetics of Ibandronate in Caucasian and Japanese Post-menopausal Women. 10th Meeting, Basel, Switzerland, 7-8 June, 2001. http://www.page-meeting.org
32. Eastell R, Barton I, Hannon RA, Chines A, Camera P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051-6.
33. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000; 11: S66-S76.
34. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586-92.
35. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomised controlled trial. Am J Med 1995; 98: 331-5.
36. Brazier M, Kamel S, Maamer M et al. Markers of bone remodelling in the elderly subject: effects of vitamin D insufficiency and its correction. J Bone Miner Res 1995; 10: 1753-61.
37. Dawson-Hughes B, Harris SS, Krall EA, Dallai GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6.
38. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42.
39. Stakkestad JA, Benevolenskaya LI, Stepan JJ et al. Three-monthly intravenous ibandronate injections: a novel treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003; 62: 969-75.
40. Cremers S, Den Sparidans RHJ, Hamdy N, Vermeij P, Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002; 57: 883-90.